Minimal Information About T Cell Assays
Names
More detailed information about this field from each metasource.
Minimal Information About T Cell Assays
metasource: Fairsharing.org
version: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
MIATA
metasource: Fairsharing.org
version: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Names
More detailed information about this field from each metasource.
Minimal Information About T Cell Assays
metasource: Fairsharing.orgversion: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
MIATA
metasource: Fairsharing.orgversion: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Names
More detailed information about this field from each metasource.
Minimal Information About T Cell Assays
metasource: Fairsharing.orgversion: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
MIATA
metasource: Fairsharing.orgversion: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
MIATA (Minimal Information About T cell Assays) enables an objective and thorough interpretation of published results from T cell assays. Due to the high similarity between T cell assays and NK cell assays the concept has been expanded to include the Minimal Information About NK cell Assays (MIANKA).
Description
More detailed information about this field from each metasource.
MIATA (Minimal Information About T cell Assays) enables an objective and thorough interpretation of published results from T cell assays. Due to the high similarity between T cell assays and NK cell assays the concept has been expanded to include the Minimal Information About NK cell Assays (MIANKA).
metasource: Fairsharing.orgversion: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Webpage:
http://miataproject.org/Webpage
More detailed information about this field from each metasource.
http://miataproject.org/
metasource: Fairsharing.orgversion: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Publications:
Publications
More detailed information about this field from each metasource.
"MIATA"-minimal information about T cell assays
PMID: 19833080
metasource: Fairsharing.org
version: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Publications
More detailed information about this field from each metasource.
"MIATA"-minimal information about T cell assays
PMID: 19833080
metasource: Fairsharing.org
version: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
-
"MIATA"-minimal information about T cell assays
PubMed citations: 96.
96 articles citing: "MIATA"-minimal information about T cell assays
Minimal Information about MHC Multimers (MIAMM). PMID:35042788
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery. PMID:33995353
Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients. PMID:33544726
A batch-effect adjusted Simon's two-stage design for cancer vaccine clinical studies. PMID:32822525
Evaluation of T-activated proteins as recall antigens to monitor Epstein-Barr virus and human cytomegalovirus-specific T cells in a clinical trial setting. PMID:32552697
CAR T cell therapy: newer approaches to counter resistance and cost. PMID:32322738
Effectiveness of Stress-Reducing Interventions on the Response to Challenges to the Immune System: A Meta-Analytic Review. PMID:31387109
Cytokine Regulation from Human Peripheral Blood Leukocytes Cultured In Vitro with Silver Doped Bioactive Glasses Microparticles. PMID:31309105
Systemic silencing of PHD2 causes reversible immune regulatory dysfunction. PMID:31162141
Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. PMID:30848084
Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. PMID:30065162
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. PMID:29891538
Minimal Information About an Immuno-Peptidomics Experiment (MIAIPE). PMID:29791771
Milieu intérieur: Defining the boundaries of a healthy immune response for improved vaccination strategies. PMID:29714672
Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. PMID:29467889
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. PMID:29385370
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. PMID:29379498
Preclinical and clinical development of neoantigen vaccines. PMID:29253113
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. PMID:28935694
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. PMID:28724573
Immunotherapy biomarkers 2016: overcoming the barriers. PMID:28653584
Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. PMID:28422751
The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization. PMID:28324192
Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. PMID:27635311
First Proposal of Minimum Information About a Cellular Assay for Regenerative Medicine. PMID:27405781
Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring. PMID:27297580
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PMID:27192170
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. PMID:27091407
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. PMID:26844233
2015 Guidance on cancer immunotherapy development in early-phase clinical studies. PMID:26767933
Immunomonitoring in glioma immunotherapy: current status and future perspectives. PMID:26638171
Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative. PMID:26608420
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. PMID:26334096
Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. PMID:26291626
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. PMID:26193344
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. PMID:26137397
Managing Multi-center Flow Cytometry Data for Immune Monitoring. PMID:26085786
Immune cell profiling to guide therapeutic decisions in rheumatic diseases. PMID:26034835
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. PMID:25982371
Cancer vaccines. PMID:25904595
Abacavir-reactive memory T cells are present in drug naïve individuals. PMID:25674793
ELISPOTs Produced by CD8 and CD4 Cells Follow Log Normal Size Distribution Permitting Objective Counting. PMID:25612115
High Reproducibility of ELISPOT Counts from Nine Different Laboratories. PMID:25585297
Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot. PMID:25424961
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. PMID:25134947
Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors. PMID:25113800
Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma. PMID:24710416
Emerging immunotherapies for rheumatoid arthritis. PMID:24535556
Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort. PMID:24524328
Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. PMID:24195078
Overnight resting of PBMC changes functional signatures of antigen specific T- cell responses: impact for immune monitoring within clinical trials. PMID:24146841
Immunological Monitoring to Rationally Guide AAV Gene Therapy. PMID:24062741
Structured reporting of T cell assay results. PMID:23882158
Systems biological approaches to measure and understand vaccine immunity in humans. PMID:23796714
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. PMID:23770775
Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform. PMID:23631706
Trial watch: Peptide vaccines in cancer therapy. PMID:23264902
Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring. PMID:23264891
Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. PMID:23252389
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. PMID:23138872
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. PMID:22986454
The immuno-oncology framework: Enabling a new era of cancer therapy. PMID:22737609
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. PMID:22729556
Harmonization of the intracellular cytokine staining assay. PMID:22714399
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. PMID:22491788
The Stanford Data Miner: a novel approach for integrating and exploring heterogeneous immunological data. PMID:22452993
Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine. PMID:22198743
New concepts for building vocabulary for cell image ontologies. PMID:22188658
Defining the critical hurdles in cancer immunotherapy. PMID:22168571
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. PMID:22020206
A methodological framework to enhance the clinical success of cancer immunotherapy. PMID:21997622
Design of therapeutic vaccines: hepatitis B as an example. PMID:21958338
Evaluation of current cancer immunotherapy: hemato-oncology. PMID:21952281
Biomarkers in T cell therapy clinical trials. PMID:21851646
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. PMID:21832238
Cancer immunotherapy--revisited. PMID:21804596
Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. PMID:21760610
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. PMID:21745365
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. PMID:21558394
Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshop. PMID:21304730
Therapeutic cancer vaccines: are we there yet? PMID:21198663
Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PMID:21179404
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. PMID:21080166
New approaches to design HIV-1 T-cell vaccines. PMID:20978376
A model for harmonizing flow cytometry in clinical trials. PMID:20959798
Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. PMID:20939860
Improved endpoints for cancer immunotherapy trials. PMID:20826737
T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. PMID:20717835
Dendritic cells: are they clinically relevant? PMID:20693842
Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference. PMID:20659333
Response definition criteria for ELISPOT assays revisited. PMID:20549207
Development and application of 'phosphoflow' as a tool for immunomonitoring. PMID:20518718
Dendritic cell subsets as vectors and targets for improved cancer therapy. PMID:20490776
An integrative paradigm to impart quality to correlative science. PMID:20233418
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. PMID:20098462
Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. PMID:20052465
Tags:
Tags
More detailed information about this field from each metasource.
assay
metasource: Fairsharing.org
version: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
immunity
metasource: Fairsharing.org
version: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
t cell
metasource: Fairsharing.org
version: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Tags
More detailed information about this field from each metasource.
assay
metasource: Fairsharing.orgversion: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
immunity
metasource: Fairsharing.orgversion: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
t cell
metasource: Fairsharing.orgversion: FAIRsharing.org: MIATA; Minimal Information About T Cell Assays; DOI: https://doi.org/10.25504/FAIRsharing.n7nqde; Last edited: Jan. 8, 2019, 1:28 p.m.; Last accessed: Jan 03 2022 7:13 p.m.
Need help integrating and/or managing biomedical data?